Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

@article{Regan2013AdjuvantTO,
  title={Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.},
  author={Meredith M. Regan and Olivia Pagani and Gini F. Fleming and Barbara A. Walley and Karen N. Price and Manuela Rabaglio and Rudolf Maibach and Barbara Ruepp and Alan S. Coates and Aron Goldhirsch and Marco Colleoni and Richard D. Gelber and Prudence A. Francis},
  journal={Breast},
  year={2013},
  volume={22 6},
  pages={1094-100}
}
OBJECTIVES In 2003 the International Breast Cancer Study Group (IBCSG) initiated the TEXT and SOFT randomized phase III trials to answer two questions concerning adjuvant treatment for premenopausal women with endocrine-responsive early breast cancer: 1-What is the role of aromatase inhibitors (AI) for women treated with ovarian function suppression (OFS)? 2-What is the role of OFS for women who remain premenopausal and are treated with tamoxifen? METHODS TEXT randomized patients to receive… CONTINUE READING